In order to personalize treatment decisions, several guidelines currently endorse routine genetic testing of four leading oncogenic drivers—EGFR, ALK, ROS1, and BRAF—in newly metastatic non-squamous NSCLC patients [3,4,5,6,7], while a number of other emerging molecular targets, such as RET and NTRK gene rearrangements, MET exon 14 skipping mutations (METΔex14), and activating HER2 mutations, are likely approaching clinical practice [8]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.